NCT01117168Active, not recruiting
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 57816 (actual)
- First submitted
- 4 May 2010
- Start date
- 30 Apr 2010
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Children's Oncology Group
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT01117168
What you commit to
- Study type: Observational
- Participants enrolled: 57816
- From 30 Apr 2010 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible:
- All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
- All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
- The benign/borderline conditions which will be reportable by agreement shall include:
- Mesoblastic nephroma.
- All teratomas, regardless of locations.
- Myeloproliferative disease
- Langerhans Cell histiocytosis
- Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
- Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
- Participant must be resident of the United States, Canada or Mexico.
Age in the registry: - to 21 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Oncology Group Coordinator of this site? Confirm its status | Arcadia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.